You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAcenocoumarol
Accession NumberDB01418
TypeSmall Molecule
GroupsApproved
Description

Acenocoumarol is a coumarin derivative used as an anticoagulant. Coumarin derivatives inhibit the reduction of vitamin K by vitamin K reductase. This prevents carboxylation of vitamin K-dependent clotting factors, II, VII, XI and X, and interferes with coagulation. Hematocrit, hemoglobin, international normalized ratio and liver panel should be monitored. Patients on acenocoumarol are prohibited from giving blood.

Structure
Thumb
Synonyms
3-(alpha-(4'-Nitrophenyl)-beta-acetylethyl)-4-hydroxycoumarin
3-(alpha-(P-Nitrophenol)-beta-acetylethyl)-4-hydroxycoumarin
3-(alpha-Acetonyl-4-nitrobenzyl)-4-hydroxycoumarin
3-(alpha-Acetonyl-P-nitrobenzyl)-4-hydroxycoumarin
3-(alpha-P-Nitrophenyl-beta-acetylethyl)-4-hydroxycoumarin
4-Hydroxy-3-(1-(4-nitrophenyl)-3-oxobutyl)-2H-1-benzopyran-2-one
4-Hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-2H-chromen-2-one
Acenocoumarin
Acenocoumarolum
Acenocumarol
Acenocumarolo
Acenokumarin
Nicoumalone
Nicumalon
Nitrophenylacetylethyl-4-hydroxycoumarine
Nitrovarfarian
Nitrowarfarin
External Identifiers Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Sintromtablet4 mgoralPaladin Labs Inc1957-12-31Not applicableCanada
Sintromtablet1 mgoralPaladin Labs Inc1962-12-31Not applicableCanada
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International Brands
NameCompany
AscumarStar
Mini-sintromNot Available
SinkumarNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIII6WP63U32H
CAS number152-72-7
WeightAverage: 353.3255
Monoisotopic: 353.089937217
Chemical FormulaC19H15NO6
InChI KeyInChIKey=VABCILAOYCMVPS-UHFFFAOYSA-N
InChI
InChI=1S/C19H15NO6/c1-11(21)10-15(12-6-8-13(9-7-12)20(24)25)17-18(22)14-4-2-3-5-16(14)26-19(17)23/h2-9,15,22H,10H2,1H3
IUPAC Name
4-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-2H-chromen-2-one
SMILES
CC(=O)CC(C1=CC=C(C=C1)[N+]([O-])=O)C1=C(O)C2=CC=CC=C2OC1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 4-hydroxycoumarins. These are coumarins that contain one or more hydroxyl groups attached to C4-position the coumarin skeleton.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassCoumarins and derivatives
Sub ClassHydroxycoumarins
Direct Parent4-hydroxycoumarins
Alternative Parents
Substituents
  • 4-hydroxycoumarin
  • 1-benzopyran
  • Benzopyran
  • Nitrobenzene
  • Pyranone
  • Benzenoid
  • Pyran
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Vinylogous acid
  • Organic nitro compound
  • Organic nitrite
  • C-nitro compound
  • Lactone
  • Ketone
  • Oxacycle
  • Organoheterocyclic compound
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Allyl-type 1,3-dipolar organic compound
  • Organic oxoazanium
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Organic zwitterion
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment and prevention of thromboembolic diseases. More specifically, it is indicated for the for the prevention of cerebral embolism, deep vein thrombosis, pulmonary embolism, thromboembolism in infarction and transient ischemic attacks. It is used for the treatment of deep vein thrombosis and myocardial infarction.
PharmacodynamicsAcenocoumarol inhibits the reduction of vitamin K by vitamin K reductase. This prevents carboxylation of certain glutamic acid residues near the N-terminals of clotting factors II, VII, IX and X, the vitamin K-dependent clotting factors. Glutamic acid carboxylation is important for the interaction between these clotting factors and calcium. Without this interaction, clotting cannot occur. Both the extrinsic (via factors VII, X and II) and intrinsic (via factors IX, X and II) are affected by acenocoumarol.
Mechanism of actionAcenocoumarol inhibits vitamin K reductase, resulting in depletion of the reduced form of vitamin K (vitamin KH2). As vitamin K is a cofactor for the carboxylation of glutamate residues on the N-terminal regions of vitamin K-dependent clotting factors, this limits the gamma-carboxylation and subsequent activation of the vitamin K-dependent coagulant proteins. The synthesis of vitamin K-dependent coagulation factors II, VII, IX, and X and anticoagulant proteins C and S is inhibited resulting in decreased prothrombin levels and a decrease in the amount of thrombin generated and bound to fibrin. This reduces the thrombogenicity of clots.
Related Articles
AbsorptionRapidly absorbed orally with greater than 60% bioavailability. Peak plasma levels are attained 1 to 3 hours following oral administration.
Volume of distribution

The volume of distribution at steady-state appeared to be significantly dose dependent: 78 ml/kg for doses < or = 20 microg/kg and 88 ml/kg for doses > 20 microg/kg respectively

Protein binding98.7% protein bound, mainly to albumin
Metabolism

Extensively metabolized in the liver via oxidation forming two hydroxy metabolites and keto reduction producing two alcohol metabolites. Reduction of the nitro group produces an amino metabolite which is further transformed to an acetoamido metabolite. Metabolites do not appear to be pharmacologically active.

SubstrateEnzymesProduct
Acenocoumarol
6-Hydroxy-R-acenocoumarolDetails
Acenocoumarol
7-Hydroxy-R-acenocoumarolDetails
Acenocoumarol
8-Hydroxy-R-acenocoumarolDetails
Route of eliminationMostly via the kidney as metabolites
Half life8 to 11 hours.
ClearanceNot Available
ToxicityThe onset and severity of the symptoms are dependent on the individual's sensitivity to oral anticoagulants, the severity of the overdosage, and the duration of treatment. Bleeding is the major sign of toxicity with oral anticoagulant drugs. The most frequent symptoms observed are: cutaneous bleeding (80%), haematuria (with renal colic) (52%), haematomas, gastrointestinal bleeding, haematemesis, uterine bleeding, epistaxis, gingival bleeding and bleeding into the joints. Further symptoms include tachycardia, hypotension, peripheral circulatory disorders due to loss of blood, nausea, vomiting, diarrhoea and abdominal pains.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Acenocoumarol Action PathwayDrug actionSMP00269
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7518
Blood Brain Barrier+0.5765
Caco-2 permeable+0.5
P-glycoprotein substrateNon-substrate0.6031
P-glycoprotein inhibitor INon-inhibitor0.7078
P-glycoprotein inhibitor IINon-inhibitor0.843
Renal organic cation transporterNon-inhibitor0.8944
CYP450 2C9 substrateNon-substrate0.6256
CYP450 2D6 substrateNon-substrate0.8936
CYP450 3A4 substrateSubstrate0.6267
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7492
Ames testAMES toxic0.6954
CarcinogenicityNon-carcinogens0.7015
BiodegradationNot ready biodegradable0.9403
Rat acute toxicity2.7869 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6326
hERG inhibition (predictor II)Non-inhibitor0.9347
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tabletoral1 mg
Tabletoral4 mg
Prices
Unit descriptionCostUnit
Sintrom 4 mg Tablet1.6USD tablet
Sintrom 1 mg Tablet0.51USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point196-199Merck Index 23
water solubilitypractically insolubleMSDS
logP1.98SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0106 mg/mLALOGPS
logP2.53ALOGPS
logP2.68ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)5.79ChemAxon
pKa (Strongest Basic)-6.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area109.42 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity94.18 m3·mol-1ChemAxon
Polarizability34.35 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Stoll, W. and Litvan, F.; U.S. Patent 2,648,682; August 11,1953; assigned to J.R. Geigy A.G.,
Switzerland.

General References
  1. Cesar JM, Garcia-Avello A, Navarro JL, Herraez MV: Aging and oral anticoagulant therapy using acenocoumarol. Blood Coagul Fibrinolysis. 2004 Oct;15(8):673-6. [PubMed:15613922 ]
  2. Lengyel M: [Warfarin or acenocoumarol is better in the anticoagulant treatment of chronic atrial fibrillation?]. Orv Hetil. 2004 Dec 26;145(52):2619-21. [PubMed:15724697 ]
  3. Ufer M: Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet. 2005;44(12):1227-46. [PubMed:16372822 ]
  4. Montes R, Ruiz de Gaona E, Martinez-Gonzalez MA, Alberca I, Hermida J: The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. Br J Haematol. 2006 Apr;133(2):183-7. [PubMed:16611310 ]
  5. Girard P, Nony P, Erhardtsen E, Delair S, Ffrench P, Dechavanne M, Boissel JP: Population pharmacokinetics of recombinant factor VIIa in volunteers anticoagulated with acenocoumarol. Thromb Haemost. 1998 Jul;80(1):109-13. [PubMed:9684795 ]
External Links
ATC CodesB01AA07
AHFS Codes
  • 20:12.04.08
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (126 KB)
Interactions
Drug Interactions
Drug
AbciximabAbciximab may increase the anticoagulant activities of Acenocoumarol.
AbirateroneThe serum concentration of Acenocoumarol can be increased when it is combined with Abiraterone.
AcetaminophenAcetaminophen may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Acenocoumarol.
AllopurinolAllopurinol may increase the anticoagulant activities of Acenocoumarol.
AlteplaseAlteplase may increase the anticoagulant activities of Acenocoumarol.
AmdinocillinAmdinocillin may increase the anticoagulant activities of Acenocoumarol.
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Acenocoumarol.
AmiodaroneAmiodarone may increase the anticoagulant activities of Acenocoumarol.
AmitriptylineAmitriptyline may increase the anticoagulant activities of Acenocoumarol.
AmorolfineAmorolfine may increase the anticoagulant activities of Acenocoumarol.
AmoxicillinAmoxicillin may increase the anticoagulant activities of Acenocoumarol.
AmpicillinAmpicillin may increase the anticoagulant activities of Acenocoumarol.
AnagrelideAnagrelide may increase the anticoagulant activities of Acenocoumarol.
AnistreplaseAnistreplase may increase the anticoagulant activities of Acenocoumarol.
ApixabanApixaban may increase the anticoagulant activities of Acenocoumarol.
ArgatrobanAcenocoumarol may increase the anticoagulant activities of Argatroban.
AzathioprineAzathioprine may decrease the anticoagulant activities of Acenocoumarol.
AzidocillinAzidocillin may increase the anticoagulant activities of Acenocoumarol.
AzlocillinAzlocillin may increase the anticoagulant activities of Acenocoumarol.
BacampicillinBacampicillin may increase the anticoagulant activities of Acenocoumarol.
BenzylpenicillinBenzylpenicillin may increase the anticoagulant activities of Acenocoumarol.
BicalutamideThe serum concentration of Acenocoumarol can be increased when it is combined with Bicalutamide.
Bismuth SubsalicylateBismuth Subsalicylate may increase the anticoagulant activities of Acenocoumarol.
BivalirudinAcenocoumarol may increase the anticoagulant activities of Bivalirudin.
BortezomibThe metabolism of Acenocoumarol can be decreased when combined with Bortezomib.
BosentanThe metabolism of Acenocoumarol can be increased when combined with Bosentan.
ButabarbitalThe metabolism of Acenocoumarol can be increased when combined with Butabarbital.
ButethalThe metabolism of Acenocoumarol can be increased when combined with Butethal.
CaffeineCaffeine may increase the anticoagulant activities of Acenocoumarol.
CalcidiolCalcidiol may decrease the anticoagulant activities of Acenocoumarol.
CalcitriolCalcitriol may decrease the anticoagulant activities of Acenocoumarol.
CangrelorCangrelor may increase the anticoagulant activities of Acenocoumarol.
CapecitabineThe serum concentration of Acenocoumarol can be increased when it is combined with Capecitabine.
CarbamazepineThe serum concentration of Acenocoumarol can be decreased when it is combined with Carbamazepine.
CarbenicillinCarbenicillin may increase the anticoagulant activities of Acenocoumarol.
CarbimazoleCarbimazole may decrease the anticoagulant activities of Acenocoumarol.
CefacetrileCefacetrile may increase the anticoagulant activities of Acenocoumarol.
CefaclorCefaclor may increase the anticoagulant activities of Acenocoumarol.
CefadroxilCefadroxil may increase the anticoagulant activities of Acenocoumarol.
CefalotinCefalotin may increase the anticoagulant activities of Acenocoumarol.
CefamandoleCefamandole may increase the anticoagulant activities of Acenocoumarol.
CefapirinCefapirin may increase the anticoagulant activities of Acenocoumarol.
CefazolinCefazolin may increase the anticoagulant activities of Acenocoumarol.
CefdinirCefdinir may increase the anticoagulant activities of Acenocoumarol.
CefditorenCefditoren may increase the anticoagulant activities of Acenocoumarol.
CefepimeCefepime may increase the anticoagulant activities of Acenocoumarol.
CefiximeCefixime may increase the anticoagulant activities of Acenocoumarol.
CefmenoximeCefmenoxime may increase the anticoagulant activities of Acenocoumarol.
CefmetazoleCefmetazole may increase the anticoagulant activities of Acenocoumarol.
CefonicidCefonicid may increase the anticoagulant activities of Acenocoumarol.
CefoperazoneCefoperazone may increase the anticoagulant activities of Acenocoumarol.
CeforanideCeforanide may increase the anticoagulant activities of Acenocoumarol.
CefotaximeCefotaxime may increase the anticoagulant activities of Acenocoumarol.
CefotetanCefotetan may increase the anticoagulant activities of Acenocoumarol.
CefotiamCefotiam may increase the anticoagulant activities of Acenocoumarol.
CefoxitinCefoxitin may increase the anticoagulant activities of Acenocoumarol.
CefpiramideCefpiramide may increase the anticoagulant activities of Acenocoumarol.
CefpodoximeCefpodoxime may increase the anticoagulant activities of Acenocoumarol.
CefprozilCefprozil may increase the anticoagulant activities of Acenocoumarol.
CefradineCefradine may increase the anticoagulant activities of Acenocoumarol.
Ceftaroline fosamilCeftaroline fosamil may increase the anticoagulant activities of Acenocoumarol.
CeftazidimeCeftazidime may increase the anticoagulant activities of Acenocoumarol.
CeftibutenCeftibuten may increase the anticoagulant activities of Acenocoumarol.
CeftizoximeCeftizoxime may increase the anticoagulant activities of Acenocoumarol.
CeftobiproleCeftobiprole may increase the anticoagulant activities of Acenocoumarol.
CeftriaxoneCeftriaxone may increase the anticoagulant activities of Acenocoumarol.
CefuroximeCefuroxime may increase the anticoagulant activities of Acenocoumarol.
CelecoxibCelecoxib may increase the anticoagulant activities of Acenocoumarol.
CephalexinCephalexin may increase the anticoagulant activities of Acenocoumarol.
CephaloglycinCephaloglycin may increase the anticoagulant activities of Acenocoumarol.
CeritinibThe serum concentration of Acenocoumarol can be increased when it is combined with Ceritinib.
Chloral hydrateThe serum concentration of Acenocoumarol can be increased when it is combined with Chloral hydrate.
ChloramphenicolChloramphenicol may increase the anticoagulant activities of Acenocoumarol.
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Acenocoumarol.
ChlorpropamideChlorpropamide may increase the anticoagulant activities of Acenocoumarol.
CholecalciferolCholecalciferol may decrease the anticoagulant activities of Acenocoumarol.
CilostazolCilostazol may increase the anticoagulant activities of Acenocoumarol.
CimetidineCimetidine may increase the anticoagulant activities of Acenocoumarol.
CitalopramCitalopram may increase the anticoagulant activities of Acenocoumarol.
Citric AcidCitric Acid may increase the anticoagulant activities of Acenocoumarol.
ClarithromycinThe serum concentration of Acenocoumarol can be increased when it is combined with Clarithromycin.
ClopidogrelClopidogrel may increase the anticoagulant activities of Acenocoumarol.
CloxacillinCloxacillin may decrease the anticoagulant activities of Acenocoumarol.
Coenzyme Q10Coenzyme Q10 may decrease the anticoagulant activities of Acenocoumarol.
ColesevelamColesevelam can cause a decrease in the absorption of Acenocoumarol resulting in a reduced serum concentration and potentially a decrease in efficacy.
CollagenaseThe risk or severity of adverse effects can be increased when Acenocoumarol is combined with Collagenase.
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Acenocoumarol is combined with Collagenase clostridium histolyticum.
CranberryCranberry may increase the anticoagulant activities of Acenocoumarol.
CyclacillinCyclacillin may increase the anticoagulant activities of Acenocoumarol.
Cyproterone acetateThe therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Cyproterone acetate.
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Acenocoumarol.
DabrafenibThe serum concentration of Acenocoumarol can be decreased when it is combined with Dabrafenib.
DalteparinDalteparin may increase the anticoagulant activities of Acenocoumarol.
DanaparoidAcenocoumarol may increase the anticoagulant activities of Danaparoid.
DasatinibDasatinib may increase the anticoagulant activities of Acenocoumarol.
DeferasiroxThe serum concentration of Acenocoumarol can be increased when it is combined with Deferasirox.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Acenocoumarol is combined with Deoxycholic Acid.
DesirudinAcenocoumarol may increase the anticoagulant activities of Desirudin.
DesmopressinDesmopressin may increase the anticoagulant activities of Acenocoumarol.
DesogestrelThe therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Desogestrel.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Acenocoumarol.
DexmethylphenidateThe serum concentration of Acenocoumarol can be increased when it is combined with Dexmethylphenidate.
DiclofenacDiclofenac may increase the anticoagulant activities of Acenocoumarol.
DicloxacillinDicloxacillin may decrease the anticoagulant activities of Acenocoumarol.
DicoumarolDicoumarol may increase the anticoagulant activities of Acenocoumarol.
DienogestThe therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Dienogest.
DiflunisalDiflunisal may increase the anticoagulant activities of Acenocoumarol.
DihydrocodeineDihydrocodeine may increase the anticoagulant activities of Acenocoumarol.
DihydrotachysterolDihydrotachysterol may decrease the anticoagulant activities of Acenocoumarol.
DihydrotestosteroneDihydrotestosterone may increase the anticoagulant activities of Acenocoumarol.
DipyridamoleDipyridamole may increase the anticoagulant activities of Acenocoumarol.
DisulfiramThe serum concentration of Acenocoumarol can be increased when it is combined with Disulfiram.
DronedaroneThe serum concentration of Acenocoumarol can be increased when it is combined with Dronedarone.
DrospirenoneDrospirenone may decrease the anticoagulant activities of Acenocoumarol.
DuloxetineDuloxetine may increase the anticoagulant activities of Acenocoumarol.
DydrogesteroneThe therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Dydrogesterone.
EconazoleThe serum concentration of Acenocoumarol can be increased when it is combined with Econazole.
Edetic AcidEdetic Acid may increase the anticoagulant activities of Acenocoumarol.
EdoxabanEdoxaban may increase the anticoagulant activities of Acenocoumarol.
EfavirenzThe serum concentration of Acenocoumarol can be decreased when it is combined with Efavirenz.
EnoxaparinAcenocoumarol may increase the anticoagulant activities of Enoxaparin.
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Acenocoumarol.
EptifibatideEptifibatide may increase the anticoagulant activities of Acenocoumarol.
ErgocalciferolErgocalciferol may decrease the anticoagulant activities of Acenocoumarol.
ErythromycinThe serum concentration of Acenocoumarol can be increased when it is combined with Erythromycin.
EscitalopramEscitalopram may increase the anticoagulant activities of Acenocoumarol.
EsomeprazoleThe serum concentration of Acenocoumarol can be increased when it is combined with Esomeprazole.
EstradiolEstradiol may decrease the anticoagulant activities of Acenocoumarol.
EstropipateEstropipate may decrease the anticoagulant activities of Acenocoumarol.
Etacrynic acidThe serum concentration of Acenocoumarol can be increased when it is combined with Ethacrynic acid.
EthanolThe serum concentration of Acenocoumarol can be decreased when it is combined with Ethanol.
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Acenocoumarol.
EthotoinEthotoin may increase the anticoagulant activities of Acenocoumarol.
Ethyl biscoumacetateEthyl biscoumacetate may increase the anticoagulant activities of Acenocoumarol.
EthynodiolEthynodiol may decrease the anticoagulant activities of Acenocoumarol.
EtodolacEtodolac may increase the anticoagulant activities of Acenocoumarol.
EtonogestrelThe therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Etonogestrel.
EtoposideEtoposide may increase the anticoagulant activities of Acenocoumarol.
ExenatideExenatide may increase the anticoagulant activities of Acenocoumarol.
FenofibrateFenofibrate may increase the anticoagulant activities of Acenocoumarol.
FenoprofenFenoprofen may increase the anticoagulant activities of Acenocoumarol.
FloctafenineFloctafenine may increase the anticoagulant activities of Acenocoumarol.
FloxuridineThe metabolism of Acenocoumarol can be decreased when combined with Floxuridine.
FlucloxacillinFlucloxacillin may decrease the anticoagulant activities of Acenocoumarol.
FluconazoleThe metabolism of Acenocoumarol can be decreased when combined with Fluconazole.
FluorouracilThe serum concentration of Acenocoumarol can be increased when it is combined with Fluorouracil.
FluoxetineFluoxetine may increase the anticoagulant activities of Acenocoumarol.
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Acenocoumarol.
FluvoxamineFluvoxamine may increase the anticoagulant activities of Acenocoumarol.
Fondaparinux sodiumAcenocoumarol may increase the anticoagulant activities of Fondaparinux sodium.
FosphenytoinFosphenytoin may increase the anticoagulant activities of Acenocoumarol.
Fusidic AcidThe serum concentration of Acenocoumarol can be increased when it is combined with Fusidic Acid.
GefitinibGefitinib may increase the anticoagulant activities of Acenocoumarol.
GestodeneThe therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Gestodene.
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Ginkgo biloba is combined with Acenocoumarol.
Glucagon recombinantGlucagon recombinant may increase the anticoagulant activities of Acenocoumarol.
GlutethimideThe metabolism of Acenocoumarol can be increased when combined with Glutethimide.
GriseofulvinThe serum concentration of Acenocoumarol can be decreased when it is combined with Griseofulvin.
HeparinAcenocoumarol may increase the anticoagulant activities of Heparin.
HeptabarbitalThe metabolism of Acenocoumarol can be increased when combined with Heptabarbital.
HetacillinHetacillin may increase the anticoagulant activities of Acenocoumarol.
HexobarbitalThe metabolism of Acenocoumarol can be increased when combined with Hexobarbital.
HomoharringtonineThe risk or severity of adverse effects can be increased when Acenocoumarol is combined with Homoharringtonine.
Hydroxyprogesterone caproateThe therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Hydroxyprogesterone caproate.
IbritumomabThe risk or severity of adverse effects can be increased when Acenocoumarol is combined with Ibritumomab.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Acenocoumarol.
IbuprofenIbuprofen may increase the anticoagulant activities of Acenocoumarol.
IcosapentIcosapent may increase the anticoagulant activities of Acenocoumarol.
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Acenocoumarol.
IfosfamideIfosfamide may increase the anticoagulant activities of Acenocoumarol.
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Acenocoumarol.
IndomethacinIndomethacin may increase the anticoagulant activities of Acenocoumarol.
InfliximabInfliximab may increase the anticoagulant activities of Acenocoumarol.
ItraconazoleThe serum concentration of Acenocoumarol can be increased when it is combined with Itraconazole.
IvermectinIvermectin may increase the anticoagulant activities of Acenocoumarol.
KetoconazoleThe serum concentration of Acenocoumarol can be increased when it is combined with Ketoconazole.
KetoprofenKetoprofen may increase the anticoagulant activities of Acenocoumarol.
KetorolacKetorolac may increase the anticoagulant activities of Acenocoumarol.
L-CarnitineL-Carnitine may increase the anticoagulant activities of Acenocoumarol.
LansoprazoleThe serum concentration of Acenocoumarol can be increased when it is combined with Lansoprazole.
LatamoxefLatamoxef may increase the anticoagulant activities of Acenocoumarol.
LeflunomideLeflunomide may increase the anticoagulant activities of Acenocoumarol.
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Acenocoumarol.
LevonorgestrelThe therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Levonorgestrel.
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Acenocoumarol.
LiothyronineLiothyronine may increase the anticoagulant activities of Acenocoumarol.
LixisenatideLixisenatide can cause a decrease in the absorption of Acenocoumarol resulting in a reduced serum concentration and potentially a decrease in efficacy.
LumacaftorThe serum concentration of Acenocoumarol can be decreased when it is combined with Lumacaftor.
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Acenocoumarol.
Medroxyprogesterone AcetateThe therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Medroxyprogesterone Acetate.
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Acenocoumarol.
Megestrol acetateThe therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Megestrol acetate.
MeloxicamMeloxicam may increase the anticoagulant activities of Acenocoumarol.
MercaptopurineMercaptopurine may decrease the anticoagulant activities of Acenocoumarol.
MestranolMestranol may decrease the anticoagulant activities of Acenocoumarol.
MethimazoleMethimazole may decrease the anticoagulant activities of Acenocoumarol.
MethohexitalThe metabolism of Acenocoumarol can be increased when combined with Methohexital.
MethylphenidateThe serum concentration of Acenocoumarol can be increased when it is combined with Methylphenidate.
MeticillinMeticillin may increase the anticoagulant activities of Acenocoumarol.
MetronidazoleThe serum concentration of Acenocoumarol can be increased when it is combined with Metronidazole.
MexiletineThe metabolism of Acenocoumarol can be decreased when combined with Mexiletine.
MezlocillinMezlocillin may increase the anticoagulant activities of Acenocoumarol.
MiconazoleThe serum concentration of Acenocoumarol can be increased when it is combined with Miconazole.
MifepristoneThe serum concentration of Acenocoumarol can be increased when it is combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Acenocoumarol.
NabumetoneNabumetone may increase the anticoagulant activities of Acenocoumarol.
NadroparinAcenocoumarol may increase the anticoagulant activities of Nadroparin.
NafcillinNafcillin may increase the anticoagulant activities of Acenocoumarol.
NaproxenNaproxen may increase the anticoagulant activities of Acenocoumarol.
NeomycinNeomycin may increase the anticoagulant activities of Acenocoumarol.
NintedanibThe risk or severity of adverse effects can be increased when Acenocoumarol is combined with Nintedanib.
NorethisteroneNorethindrone may decrease the anticoagulant activities of Acenocoumarol.
NorgestimateNorgestimate may decrease the anticoagulant activities of Acenocoumarol.
ObinutuzumabThe risk or severity of adverse effects can be increased when Acenocoumarol is combined with Obinutuzumab.
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Acenocoumarol.
Omega-3-acid ethyl estersOmega-3-acid ethyl esters may increase the anticoagulant activities of Acenocoumarol.
OmeprazoleThe serum concentration of Acenocoumarol can be increased when it is combined with Omeprazole.
OritavancinThe serum concentration of Acenocoumarol can be increased when it is combined with Oritavancin.
OxacillinOxacillin may increase the anticoagulant activities of Acenocoumarol.
OxandroloneOxandrolone may increase the anticoagulant activities of Acenocoumarol.
OxaprozinOxaprozin may increase the anticoagulant activities of Acenocoumarol.
OxytetracyclineOxytetracycline may increase the anticoagulant activities of Acenocoumarol.
ParoxetineParoxetine may increase the anticoagulant activities of Acenocoumarol.
Peginterferon alfa-2bThe serum concentration of Acenocoumarol can be increased when it is combined with Peginterferon alfa-2b.
PentobarbitalThe metabolism of Acenocoumarol can be increased when combined with Pentobarbital.
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Acenocoumarol.
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Acenocoumarol.
PhenindionePhenindione may increase the anticoagulant activities of Acenocoumarol.
PhenoxymethylpenicillinPhenoxymethylpenicillin may increase the anticoagulant activities of Acenocoumarol.
PhenprocoumonPhenprocoumon may increase the anticoagulant activities of Acenocoumarol.
PhenytoinPhenytoin may increase the anticoagulant activities of Acenocoumarol.
PhylloquinonePhylloquinone may decrease the anticoagulant activities of Acenocoumarol.
PiperacillinPiperacillin may increase the anticoagulant activities of Acenocoumarol.
PiroxicamPiroxicam may increase the anticoagulant activities of Acenocoumarol.
PivampicillinPivampicillin may increase the anticoagulant activities of Acenocoumarol.
PivmecillinamPivmecillinam may increase the anticoagulant activities of Acenocoumarol.
PosaconazoleThe serum concentration of Acenocoumarol can be increased when it is combined with Posaconazole.
PrasugrelPrasugrel may increase the anticoagulant activities of Acenocoumarol.
PravastatinPravastatin may increase the anticoagulant activities of Acenocoumarol.
PrimidoneThe metabolism of Acenocoumarol can be increased when combined with Primidone.
ProgesteroneThe therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Progesterone.
PropacetamolPropacetamol may increase the anticoagulant activities of Acenocoumarol.
PropafenoneThe serum concentration of Acenocoumarol can be increased when it is combined with Propafenone.
PropylthiouracilPropylthiouracil may decrease the anticoagulant activities of Acenocoumarol.
QuinidineQuinidine may increase the anticoagulant activities of Acenocoumarol.
QuinineQuinine may increase the anticoagulant activities of Acenocoumarol.
ReteplaseReteplase may increase the anticoagulant activities of Acenocoumarol.
RidogrelRidogrel may increase the anticoagulant activities of Acenocoumarol.
RifabutinThe metabolism of Acenocoumarol can be increased when combined with Rifabutin.
RivaroxabanAcenocoumarol may increase the anticoagulant activities of Rivaroxaban.
SalsalateSalsalate may increase the anticoagulant activities of Acenocoumarol.
SecobarbitalThe metabolism of Acenocoumarol can be increased when combined with Secobarbital.
SertralineSertraline may increase the anticoagulant activities of Acenocoumarol.
SparfloxacinSparfloxacin may increase the anticoagulant activities of Acenocoumarol.
St. John's WortThe metabolism of Acenocoumarol can be increased when combined with St. John&#39;s Wort.
StreptokinaseStreptokinase may increase the anticoagulant activities of Acenocoumarol.
SucralfateSucralfate may decrease the anticoagulant activities of Acenocoumarol.
SugammadexSugammadex may increase the anticoagulant activities of Acenocoumarol.
SulfinpyrazoneThe metabolism of Acenocoumarol can be decreased when combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Acenocoumarol can be decreased when combined with Sulfisoxazole.
SulindacSulindac may increase the anticoagulant activities of Acenocoumarol.
SulodexideSulodexide may increase the anticoagulant activities of Acenocoumarol.
TamoxifenThe serum concentration of Acenocoumarol can be increased when it is combined with Tamoxifen.
TegafurThe serum concentration of Acenocoumarol can be increased when it is combined with Tegafur.
TenecteplaseTenecteplase may increase the anticoagulant activities of Acenocoumarol.
TeriflunomideThe serum concentration of Acenocoumarol can be decreased when it is combined with Teriflunomide.
TestosteroneTestosterone may increase the anticoagulant activities of Acenocoumarol.
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Acenocoumarol.
TiboloneTibolone may increase the anticoagulant activities of Acenocoumarol.
TicagrelorTicagrelor may increase the anticoagulant activities of Acenocoumarol.
TicarcillinTicarcillin may increase the anticoagulant activities of Acenocoumarol.
TiclopidineTiclopidine may increase the anticoagulant activities of Acenocoumarol.
TinzaparinAcenocoumarol may increase the anticoagulant activities of Tinzaparin.
TipranavirTipranavir may increase the anticoagulant activities of Acenocoumarol.
TirofibanTirofiban may increase the anticoagulant activities of Acenocoumarol.
TolmetinTolmetin may increase the anticoagulant activities of Acenocoumarol.
ToremifeneToremifene may increase the anticoagulant activities of Acenocoumarol.
TositumomabThe risk or severity of adverse effects can be increased when Acenocoumarol is combined with Tositumomab.
TramadolTramadol may increase the anticoagulant activities of Acenocoumarol.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Acenocoumarol.
UrokinaseUrokinase may increase the anticoagulant activities of Acenocoumarol.
VemurafenibThe serum concentration of Acenocoumarol can be increased when it is combined with Vemurafenib.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Acenocoumarol.
VilazodoneVilazodone may increase the anticoagulant activities of Acenocoumarol.
Vitamin EVitamin E may increase the anticoagulant activities of Acenocoumarol.
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Acenocoumarol.
VoriconazoleThe serum concentration of Acenocoumarol can be increased when it is combined with Voriconazole.
VorinostatVorinostat may increase the anticoagulant activities of Acenocoumarol.
VortioxetineVortioxetine may increase the anticoagulant activities of Acenocoumarol.
WarfarinAcenocoumarol may increase the anticoagulant activities of Warfarin.
ZafirlukastThe serum concentration of Acenocoumarol can be increased when it is combined with Zafirlukast.
Food Interactions
  • High doses of vitamin A, C, E and K (e.g. avocado, green vegetables)

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Vitamin-k-epoxide reductase (warfarin-sensitive) activity
Specific Function:
Involved in vitamin K metabolism. Catalytic subunit of the vitamin K epoxide reductase (VKOR) complex which reduces inactive vitamin K 2,3-epoxide to active vitamin K. Vitamin K is required for the gamma-carboxylation of various proteins, including clotting factors, and is required for normal blood coagulation, but also for normal bone development.
Gene Name:
VKORC1
Uniprot ID:
Q9BQB6
Molecular Weight:
18234.3 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, Jaillon P, Beaune P, Laurent-Puig P, Becquemont L, Loriot MA: Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood. 2005 Jul 1;106(1):135-40. Epub 2005 Mar 24. [PubMed:15790782 ]
  3. Gonzalez-Conejero R, Corral J, Roldan V, Ferrer F, Sanchez-Serrano I, Sanchez-Blanco JJ, Marin F, Vicente V: The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol. J Thromb Haemost. 2007 Aug;5(8):1701-6. Epub 2007 May 21. [PubMed:17596133 ]
  4. Montes R, Ruiz de Gaona E, Martinez-Gonzalez MA, Alberca I, Hermida J: The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. Br J Haematol. 2006 Apr;133(2):183-7. [PubMed:16611310 ]
  5. Rettie AE, Farin FM, Beri NG, Srinouanprachanh SL, Rieder MJ, Thijssen HH: A case study of acenocoumarol sensitivity and genotype-phenotype discordancy explained by combinations of polymorphisms in VKORC1 and CYP2C9. Br J Clin Pharmacol. 2006 Nov;62(5):617-20. Epub 2006 Jul 21. [PubMed:16869821 ]
  6. Schalekamp T, Brasse BP, Roijers JF, Chahid Y, van Geest-Daalderop JH, de Vries-Goldschmeding H, van Wijk EM, Egberts AC, de Boer A: VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther. 2006 Jul;80(1):13-22. [PubMed:16815313 ]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Stehle S, Kirchheiner J, Lazar A, Fuhr U: Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin Pharmacokinet. 2008;47(9):565-94. [PubMed:18698879 ]
  3. Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C, Jaillon P, Beaune P, Laurent-Puig P, Becquemont L, Loriot MA: Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood. 2005 Jul 1;106(1):135-40. Epub 2005 Mar 24. [PubMed:15790782 ]
  4. Gonzalez-Conejero R, Corral J, Roldan V, Ferrer F, Sanchez-Serrano I, Sanchez-Blanco JJ, Marin F, Vicente V: The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol. J Thromb Haemost. 2007 Aug;5(8):1701-6. Epub 2007 May 21. [PubMed:17596133 ]
  5. Montes R, Ruiz de Gaona E, Martinez-Gonzalez MA, Alberca I, Hermida J: The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. Br J Haematol. 2006 Apr;133(2):183-7. [PubMed:16611310 ]
  6. Rettie AE, Farin FM, Beri NG, Srinouanprachanh SL, Rieder MJ, Thijssen HH: A case study of acenocoumarol sensitivity and genotype-phenotype discordancy explained by combinations of polymorphisms in VKORC1 and CYP2C9. Br J Clin Pharmacol. 2006 Nov;62(5):617-20. Epub 2006 Jul 21. [PubMed:16869821 ]
  7. Schalekamp T, Brasse BP, Roijers JF, Chahid Y, van Geest-Daalderop JH, de Vries-Goldschmeding H, van Wijk EM, Egberts AC, de Boer A: VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther. 2006 Jul;80(1):13-22. [PubMed:16815313 ]
  8. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Ufer M: Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet. 2005;44(12):1227-46. [PubMed:16372822 ]
  2. Morales-Molina JA, Arrebola MA, Robles PA, Mangana JC: Possible interaction between topical terbinafine and acenocoumarol. Ann Pharmacother. 2009 Nov;43(11):1911-2. doi: 10.1345/aph.1M299. Epub 2009 Oct 20. [PubMed:19843835 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Fitos I, Visy J, Simonyi M, Hermansson J: Stereoselective distribution of acenocoumarol enantiomers in human plasma: chiral chromatographic analysis of the ultrafiltrates. Chirality. 1993;5(5):346-9. [PubMed:8398591 ]
  2. Fitos I, Visy J, Magyar A, Kajtar J, Simonyi M: Inverse stereoselectivity in the binding of acenocoumarol to human serum albumin and to alpha 1-acid glycoprotein. Biochem Pharmacol. 1989 Jul 15;38(14):2259-62. [PubMed:2751692 ]
  3. Otagiri M, Fleitman JS, Perrin JH: Investigations into the binding of phenprocoumon to albumin using fluorescence spectroscopy. J Pharm Pharmacol. 1980 Jul;32(7):478-82. [PubMed:6105183 ]
Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Fitos I, Visy J, Simonyi M, Hermansson J: Stereoselective distribution of acenocoumarol enantiomers in human plasma: chiral chromatographic analysis of the ultrafiltrates. Chirality. 1993;5(5):346-9. [PubMed:8398591 ]
  2. Fitos I, Visy J, Magyar A, Kajtar J, Simonyi M: Inverse stereoselectivity in the binding of acenocoumarol to human serum albumin and to alpha 1-acid glycoprotein. Biochem Pharmacol. 1989 Jul 15;38(14):2259-62. [PubMed:2751692 ]
  3. Hazai E, Visy J, Fitos I, Bikadi Z, Simonyi M: Selective binding of coumarin enantiomers to human alpha1-acid glycoprotein genetic variants. Bioorg Med Chem. 2006 Mar 15;14(6):1959-65. Epub 2005 Nov 15. [PubMed:16290938 ]
Comments
comments powered by Disqus
Drug created on July 24, 2007 02:32 / Updated on March 26, 2014 16:06